Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
30.50
-0.39 (-1.26%)
At close: Sep 2, 2026, 4:00 PM EDT
30.17
-0.33 (-1.08%)
Pre-market: Sep 3, 2026, 7:18 AM EDT
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $9.33M in the quarter ending June 30, 2026, a decrease of -32.51%. This brings the company's revenue in the last twelve months to $27.59M, down -86.20% year-over-year. In the year 2025, Stoke Therapeutics had annual revenue of $184.42M with 404.50% growth.
Revenue (ttm)
$27.59M
Revenue Growth
-86.20%
P/S Ratio
71.34
Revenue / Employee
$162,282
Employees
170
Market Cap
1.97B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 184.42M | 147.87M | 404.50% |
| Dec 31, 2024 | 36.56M | 27.78M | 316.34% |
| Dec 31, 2023 | 8.78M | -3.63M | -29.22% |
| Dec 31, 2022 | 12.41M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ADMA Biologics | 512.28M |
| Immunocore Holdings | 430.78M |
| Vericel | 306.30M |
| Vir Biotechnology | 303.23M |
| Maravai LifeSciences Holdings | 208.78M |
| Xencor | 104.97M |
| Agios Pharmaceuticals | 98.34M |
| Nanobiotix | 38.27M |
STOK News
- 23 hours ago - Stoke Therapeutics to Present at the Cantor Global Healthcare Conference - Business Wire
- 2 days ago - Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate - TheFly
- 13 days ago - Stoke Therapeutics reinstated with an Overweight at JPMorgan - TheFly
- 15 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 21 days ago - Stoke Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 4 weeks ago - Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference - Business Wire
- 4 weeks ago - Stoke Therapeutics price target lowered to $58 from $60 at Canaccord - TheFly
- 4 weeks ago - Stoke Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts